Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 4, OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2% IN THE TREATMENT OF SEBORRHEIC DERMATITIS

NCT00703846 is registered in ClinicalTrials.gov with Stiefel, a GSK Company as lead sponsor.

NCT NCT00703846
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00703846 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 4, OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2% IN THE TREATMENT OF SEBORRHEIC DERMATITIS
Lead sponsor
Stiefel, a GSK Company
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2008
Completion date
April 30, 2010
Enrollment
498 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

dermatitis, seborrheic